Clinical Trial

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Study acronym: MagnetisMM15
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Protocol Amendment History 3 changes
notable Trial sites expanded: 28 -> 33 locations 2026-06-17
notable Trial sites expanded: 15 -> 28 locations 2026-05-15
notable Trial sites reduced: 28 -> 15 locations 2026-05-06
Trial Details
NCT Number NCT06057402
Lead Sponsor Pfizer
Conditions Multiple Myeloma
Enrollment 80 participants
Start Date 2023-10-03
Primary Completion 2032-02-22 (estimated)
Study Completion 2032-02-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-01